[
  {
    "ts": "2025-12-16T12:00:00+00:00",
    "headline": "Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)",
    "summary": "Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated muzastotug, in combination with Merck’s (known as MSD outside of the United States and Canada) anti-PD",
    "url": "https://finance.yahoo.com/news/adagene-announces-fda-fast-track-120000846.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "57994114-386d-3307-9983-571024ec9741",
      "content": {
        "id": "57994114-386d-3307-9983-571024ec9741",
        "contentType": "STORY",
        "title": "Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)",
        "description": "",
        "summary": "Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated muzastotug, in combination with Merck’s (known as MSD outside of the United States and Canada) anti-PD",
        "pubDate": "2025-12-16T12:00:00Z",
        "displayTime": "2025-12-16T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/fe1e492df597a586d8304ad7fbea4a8b",
          "originalWidth": 440,
          "originalHeight": 386,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Km.iDUymrS8htWjo9.aZZg--~B/aD0zODY7dz00NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/fe1e492df597a586d8304ad7fbea4a8b.cf.webp",
              "width": 440,
              "height": 386,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ND76FpkFurDCgVBykGeoxg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/fe1e492df597a586d8304ad7fbea4a8b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/adagene-announces-fda-fast-track-120000846.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/adagene-announces-fda-fast-track-120000846.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ADAG"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-16T13:00:00+00:00",
    "headline": "Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace",
    "summary": "The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial’s targeted enrolmentStrong operational progress continues globally with over 120 activated clinical sites and 27 countries having received full regulatory approvals including the United States Futility analysis remains on track for the first quarter of CY2026 and completion of patient enrolment in the third quarter of CY2026 SYDNEY, AUSTRALIA, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: I",
    "url": "https://finance.yahoo.com/news/immutep-announces-strong-operational-progress-130000779.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "0f76b99b-4c80-335e-a8a4-02c945f66c10",
      "content": {
        "id": "0f76b99b-4c80-335e-a8a4-02c945f66c10",
        "contentType": "STORY",
        "title": "Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace",
        "description": "",
        "summary": "The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial’s targeted enrolmentStrong operational progress continues globally with over 120 activated clinical sites and 27 countries having received full regulatory approvals including the United States Futility analysis remains on track for the first quarter of CY2026 and completion of patient enrolment in the third quarter of CY2026 SYDNEY, AUSTRALIA, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: I",
        "pubDate": "2025-12-16T13:00:00Z",
        "displayTime": "2025-12-16T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/cd983e6beca4b018d9b3ca144b589600",
          "originalWidth": 382,
          "originalHeight": 131,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/u4trPsLT_6BovPoxYBoPLA--~B/aD0xMzE7dz0zODI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/cd983e6beca4b018d9b3ca144b589600.cf.webp",
              "width": 382,
              "height": 131,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/p_wD857bCxFbkXu3hRgrgA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/cd983e6beca4b018d9b3ca144b589600.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/immutep-announces-strong-operational-progress-130000779.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/immutep-announces-strong-operational-progress-130000779.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IMMP"
            },
            {
              "symbol": "PRRUF"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]